Bernd Eisele

1.9k total citations
20 papers, 1.4k citations indexed

About

Bernd Eisele is a scholar working on Immunology, Infectious Diseases and Surgery. According to data from OpenAlex, Bernd Eisele has authored 20 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 7 papers in Infectious Diseases and 6 papers in Surgery. Recurrent topics in Bernd Eisele's work include Tuberculosis Research and Epidemiology (7 papers), Immune responses and vaccinations (7 papers) and Immunodeficiency and Autoimmune Disorders (6 papers). Bernd Eisele is often cited by papers focused on Tuberculosis Research and Epidemiology (7 papers), Immune responses and vaccinations (7 papers) and Immunodeficiency and Autoimmune Disorders (6 papers). Bernd Eisele collaborates with scholars based in Germany, Netherlands and South Africa. Bernd Eisele's co-authors include Stefan H. E. Kaufmann, Leander Grode, C. Erik Hack, Maurice Redondo, Walter A. Wuillemin, Sacha Zeerleder, Christoph Caliezi, L. G. Thijs, U. Delvos and H.-P. Schuster and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Bernd Eisele

19 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernd Eisele Germany 15 720 539 420 269 186 20 1.4k
Pascale E. P. Dekkers Netherlands 16 501 0.7× 117 0.2× 388 0.9× 358 1.3× 54 0.3× 34 1.2k
Doris M. Ponce United States 16 239 0.3× 292 0.5× 274 0.7× 690 2.6× 148 0.8× 97 1.3k
Carlos Rodríguez‐Gallego Spain 27 848 1.2× 167 0.3× 379 0.9× 76 0.3× 73 0.4× 77 1.6k
Parastoo B. Dahi United States 18 229 0.3× 304 0.6× 249 0.6× 494 1.8× 141 0.8× 111 1.7k
Saveria Capria Italy 19 186 0.3× 206 0.4× 278 0.7× 543 2.0× 163 0.9× 70 1.3k
Melinda M. Dean Australia 18 620 0.9× 124 0.2× 276 0.7× 162 0.6× 63 0.3× 57 1.1k
Shubhra Ghosh United States 13 266 0.4× 274 0.5× 711 1.7× 520 1.9× 85 0.5× 27 1.4k
Donna Salzman United States 18 114 0.2× 302 0.6× 372 0.9× 358 1.3× 105 0.6× 57 1.2k
Philip Wood United Kingdom 19 632 0.9× 140 0.3× 136 0.3× 183 0.7× 143 0.8× 31 1.2k
PJ Tutschka United States 19 337 0.5× 158 0.3× 226 0.5× 1.1k 3.9× 201 1.1× 42 1.5k

Countries citing papers authored by Bernd Eisele

Since Specialization
Citations

This map shows the geographic impact of Bernd Eisele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Eisele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Eisele more than expected).

Fields of papers citing papers by Bernd Eisele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Eisele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Eisele. The network helps show where Bernd Eisele may publish in the future.

Co-authorship network of co-authors of Bernd Eisele

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Eisele. A scholar is included among the top collaborators of Bernd Eisele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Eisele. Bernd Eisele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Loxton, André G., Leander Grode, Andrea Gutschmidt, et al.. (2017). Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clinical and Vaccine Immunology. 24(2). 108 indexed citations
3.
Nieuwenhuizen, Natalie E., Prasad S. Kulkarni, Umesh Shaligram, et al.. (2017). The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. Frontiers in Immunology. 8. 1147–1147. 139 indexed citations
4.
Grode, Leander, Mark F. Cotton, Gerhard Walzl, et al.. (2014). VPM1002: A new TB prime vaccine on the horizon. Pneumologie. 68(2). 1 indexed citations
5.
Kaufmann, Stefan H. E., Mark F. Cotton, Bernd Eisele, et al.. (2014). The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Review of Vaccines. 13(5). 619–630. 62 indexed citations
6.
Rentsch, Cyrill A., Christian Wetterauer, Joël Gsponer, et al.. (2014). 521 VPM1002 – a recombinant BCG with favourable preclinical toxicity and immunogenicity for potential improvement of BCG immunotherapy for non-muscle invasive bladder cancer. European Urology Supplements. 13(1). e521–e521. 2 indexed citations
7.
Grode, Leander, Christian A. Ganoza, Christiane Brohm, et al.. (2013). Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine. 31(9). 1340–1348. 152 indexed citations
8.
Grode, Leander, Megan B. Fitzpatrick, Dominick J. Laddy, et al.. (2013). Nonclinical Development of BCG Replacement Vaccine Candidates. SHILAP Revista de lepidopterología. 1(2). 120–138. 28 indexed citations
9.
Desel, Christiane, Anca Dorhoi, Silke Bandermann, et al.. (2011). Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses. The Journal of Infectious Diseases. 204(10). 1573–1584. 127 indexed citations
10.
11.
Gänsbacher, Bernd, T. Brill, Bernd Eisele, et al.. (2007). Cancer gene therapy with a retrovirally transduced IL2-IFNγ-secreting allogeneic tumorvaccine in patients with progressive hormone refractory prostate cancer—A phase I/II trial. Journal of Clinical Oncology. 25(18_suppl). 5127–5127. 1 indexed citations
12.
Caliezi, Christoph, Walter A. Wuillemin, Sacha Zeerleder, et al.. (2000). C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema. Pharmacological Reviews. 52(1). 91–112. 247 indexed citations
13.
Jansen, Patty M., et al.. (1998). Effect of C1 Inhibitor on Inflammatory and Physiologic Response Patterns in Primates Suffering from Lethal Septic Shock. The Journal of Immunology. 160(1). 475–484. 72 indexed citations
14.
Eisele, Bernd & Maurice Lamy. (1998). Clinical Experience with Antithrombin III Concentrates in Critically III Patients with Sepsis and Multiple Organ Failure. Seminars in Thrombosis and Hemostasis. 24(1). 71–80. 23 indexed citations
15.
Eisele, Bernd, H. Heinrichs, U. Delvos, et al.. (1998). Antithrombin III in patients with severe sepsis. Intensive Care Medicine. 24(7). 663–672. 232 indexed citations
16.
Lamy, Maurice & Bernd Eisele. (1996). Antithrombin III in the therapy of severe sepsis. Open Repository and Bibliography (University of Liège). 9.
17.
Salat, Christoph, Ernst Holler, Michael Schleuning, et al.. (1995). Levels of the terminal complement complex, C3a-desArg and C1-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation. Annals of Hematology. 71(6). 271–274. 20 indexed citations
18.
Hack, C. Erik, Aernout C. Ogilvie, Bernd Eisele, et al.. (1994). Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy.. PubMed. 388. 335–57. 31 indexed citations
19.
Nürnberger, W., Reinhart Willers, Bernd Eisele, et al.. (1993). Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Annals of Hematology. 67(1). 17–21. 15 indexed citations
20.
Hack, C. Erik, Aernout C. Ogilvie, Bernd Eisele, et al.. (1993). C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Medicine. 19(S1). S19–S28. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pascale E. P. Dekkers Breakdown of academic impact, for papers by Doris M. Ponce Breakdown of academic impact, for papers by Carlos Rodríguez‐Gallego Breakdown of academic impact, for papers by Parastoo B. Dahi Breakdown of academic impact, for papers by Saveria Capria Breakdown of academic impact, for papers by Melinda M. Dean Breakdown of academic impact, for papers by Shubhra Ghosh Breakdown of academic impact, for papers by Donna Salzman Breakdown of academic impact, for papers by Philip Wood Breakdown of academic impact, for papers by PJ Tutschka
Rankless by CCL
2026